Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22006157 | 1.00 | TSHR (0.31) | TSHRCA1CA2CA4 | |
| SCHEMBL15077614 | 1.00 | TSHR (0.31) | TSHRCA1CA2CA4 | |
| SCHEMBL27386480 | 1.00 | TSHR (0.31) | TSHRCA1CA2CA4 | |
| SCHEMBL17803280 | 1.00 | TSHR (0.31) | TSHRCA1CA2CA4 | |
| SCHEMBL11217184 | 0.84 | TSHR (0.44) | TSHRCA1CA2CA4 | |
| SCHEMBL561318 | 0.84 | TSHR (0.44) | TSHRCA1CA2CA4 | |
| SCHEMBL22451052 | 0.81 | — | — | |
| SCHEMBL14923183 | 0.80 | CA1 (0.39) | CA1CA2CA4 | |
| Nitric Acid SCHEMBL10744127 | 0.78 | CA5A (0.44) | CA2 | |
| SCHEMBL239138 | 0.75 | CA1 (0.40) | TSHRCA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-01 | — | — | US | disclosed |
| US-8585924-B2 | Compound having bicyclo[3.3.0]octane-2,6-diyl, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20120286200-A1 | COMPOUND HAVING BICYCLO[3.3.0]OCTANE-2,6-DIYL, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-11-15 | — | — | US | disclosed |
| US-20120286200-A1 | COMPOUND HAVING BICYCLO[3.3.0]OCTANE-2,6-DIYL, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120286200-A1 | COMPOUND HAVING BICYCLO[3.3.0]OCTANE-2,6-DIYL, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CCDC22, PIEZO1, OCIAD2 | TSHR 4458/4885CA1 1285/4885CA2 1880/4885 |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | CNR1, SCN1B, OPRL1 | TSHR 575/4885CA1 781/4885CA2 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.